Lupin eyes acquisitions in various global markets

29 Dec 2014 Evaluate

In a bid to bolster its presence overseas, drug major Lupin is eyeing acquisitions in various global markets, including the US, Latin America and Europe. The company, which has already entered the Mexican market, would also continue to look for acquisitions in key Latam markets such as Brazil.

During the last fiscal, global markets (excluding India) accounted for around 75 per cent of the company’s total revenues, which stood over Rs 11,000 crore.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin Share Price

2133.05 11.40 (0.54%)
29-Jan-2026 14:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1210.20
Cipla 1324.55
Zydus Lifesciences 889.90
Lupin 2133.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×